MX2021013858A - Moduladores y modulación del arn de receptor para productos finales de glicación avanzada. - Google Patents
Moduladores y modulación del arn de receptor para productos finales de glicación avanzada.Info
- Publication number
- MX2021013858A MX2021013858A MX2021013858A MX2021013858A MX2021013858A MX 2021013858 A MX2021013858 A MX 2021013858A MX 2021013858 A MX2021013858 A MX 2021013858A MX 2021013858 A MX2021013858 A MX 2021013858A MX 2021013858 A MX2021013858 A MX 2021013858A
- Authority
- MX
- Mexico
- Prior art keywords
- end products
- modulators
- advanced glycation
- glycation end
- receptor rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901641A AU2019901641A0 (en) | 2019-05-14 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902095A AU2019902095A0 (en) | 2019-06-17 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019902772A AU2019902772A0 (en) | 2019-08-02 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| AU2019903900A AU2019903900A0 (en) | 2019-10-16 | Modulators and Modulation of the Receptor for Advanced Glycation End-Products RNA | |
| PCT/AU2020/050449 WO2020227758A1 (en) | 2019-05-14 | 2020-05-07 | Modulators and modulation of the receptor for advanced glycation end-products rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013858A true MX2021013858A (es) | 2022-03-22 |
Family
ID=73290056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013858A MX2021013858A (es) | 2019-05-14 | 2020-05-07 | Moduladores y modulación del arn de receptor para productos finales de glicación avanzada. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11441148B2 (enExample) |
| EP (1) | EP3969590A4 (enExample) |
| JP (2) | JP2022533358A (enExample) |
| KR (1) | KR20220009971A (enExample) |
| CN (1) | CN114127288A (enExample) |
| AU (2) | AU2020276337B2 (enExample) |
| BR (1) | BR112021022714A2 (enExample) |
| CA (1) | CA3140209A1 (enExample) |
| IL (1) | IL288040A (enExample) |
| MX (1) | MX2021013858A (enExample) |
| SG (1) | SG11202112144RA (enExample) |
| WO (1) | WO2020227758A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220009971A (ko) | 2019-05-14 | 2022-01-25 | 모나쉬 유니버시티 | 최종당화산물 수용체 알엔에이의 조절인자 및 조절 |
| JP2026516053A (ja) * | 2023-05-05 | 2026-05-19 | レイジ バイオテック ピーティワイ エルティーディー | オリゴヌクレオチドの投与 |
| AU2023447004A1 (en) * | 2023-05-05 | 2025-10-16 | RAGE Biotech Pty Ltd | Methods of monitoring splicing |
| KR20260027924A (ko) * | 2023-05-19 | 2026-03-03 | 레이지 바이오텍 피티와이 리미티드 | 연기 노출의 영향 최소화 방법 |
| JP2026518714A (ja) * | 2023-05-19 | 2026-06-09 | レイジ バイオテック ピーティワイ エルティーディー | 肺線維症を治療する方法 |
| EP4768586A1 (en) * | 2023-09-27 | 2026-07-01 | Changchun Genescience Pharmaceutical Co., Ltd. | NEW ARNSI, COMPOSITION, INCLUDING IT AND USE |
| AU2024359647A1 (en) * | 2023-10-12 | 2026-03-12 | RAGE Biotech Pty Ltd | Rnai agents targeting rage |
| WO2025222258A1 (en) * | 2024-04-24 | 2025-10-30 | RAGE Biotech Pty Ltd | Methods of treating or preventing obstructive pulmonary disease |
| WO2025236048A1 (en) * | 2024-05-17 | 2025-11-20 | RAGE Biotech Pty Ltd | Methods of treating the effects of smoke |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
| US20020123476A1 (en) | 1991-03-19 | 2002-09-05 | Emanuele R. Martin | Therapeutic delivery compositions and methods of use thereof |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| WO1997022371A1 (en) | 1995-12-18 | 1997-06-26 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| AU3243300A (en) | 1999-02-23 | 2000-09-14 | Isis Pharmaceuticals, Inc. | Multiparticulate formulation |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| JP3837494B2 (ja) | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| US6905827B2 (en) * | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US7026121B1 (en) * | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| AU2006242371A1 (en) * | 2005-04-29 | 2006-11-09 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of nucleic acid at post-transcriptional level |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| JP2010233542A (ja) * | 2009-03-31 | 2010-10-21 | Kanazawa Univ | Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ |
| US20100303776A1 (en) * | 2009-04-16 | 2010-12-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of multiple nucleic acids |
| WO2013027104A1 (en) | 2011-08-25 | 2013-02-28 | Db Equipment As | Accessory bag having reinforced sidewalls and variable length |
| US20210246454A1 (en) * | 2018-05-17 | 2021-08-12 | Lifesplice Pharma Llc | Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use |
| KR20220009971A (ko) | 2019-05-14 | 2022-01-25 | 모나쉬 유니버시티 | 최종당화산물 수용체 알엔에이의 조절인자 및 조절 |
-
2020
- 2020-05-07 KR KR1020217039458A patent/KR20220009971A/ko active Pending
- 2020-05-07 MX MX2021013858A patent/MX2021013858A/es unknown
- 2020-05-07 BR BR112021022714A patent/BR112021022714A2/pt unknown
- 2020-05-07 EP EP20806464.2A patent/EP3969590A4/en active Pending
- 2020-05-07 WO PCT/AU2020/050449 patent/WO2020227758A1/en not_active Ceased
- 2020-05-07 CA CA3140209A patent/CA3140209A1/en active Pending
- 2020-05-07 AU AU2020276337A patent/AU2020276337B2/en active Active
- 2020-05-07 JP JP2021568406A patent/JP2022533358A/ja active Pending
- 2020-05-07 SG SG11202112144RA patent/SG11202112144RA/en unknown
- 2020-05-07 CN CN202080044288.6A patent/CN114127288A/zh active Pending
-
2021
- 2021-08-25 US US17/411,932 patent/US11441148B2/en active Active
- 2021-11-11 IL IL288040A patent/IL288040A/en unknown
-
2022
- 2022-09-07 US US17/930,364 patent/US11674143B2/en active Active
-
2023
- 2023-05-01 US US18/310,289 patent/US12565656B2/en active Active
-
2025
- 2025-04-02 JP JP2025061149A patent/JP2025106369A/ja active Pending
- 2025-08-29 AU AU2025223886A patent/AU2025223886A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020227758A1 (en) | 2020-11-19 |
| WO2020227758A8 (en) | 2021-11-18 |
| US20230015481A1 (en) | 2023-01-19 |
| JP2022533358A (ja) | 2022-07-22 |
| US12565656B2 (en) | 2026-03-03 |
| JP2025106369A (ja) | 2025-07-15 |
| CN114127288A (zh) | 2022-03-01 |
| US20240141360A1 (en) | 2024-05-02 |
| BR112021022714A2 (pt) | 2022-01-18 |
| KR20220009971A (ko) | 2022-01-25 |
| US20210388363A1 (en) | 2021-12-16 |
| CA3140209A1 (en) | 2020-11-19 |
| EP3969590A1 (en) | 2022-03-23 |
| SG11202112144RA (en) | 2021-11-29 |
| US11674143B2 (en) | 2023-06-13 |
| AU2020276337B2 (en) | 2025-05-29 |
| AU2025223886A1 (en) | 2025-09-18 |
| US11441148B2 (en) | 2022-09-13 |
| AU2020276337A1 (en) | 2021-12-02 |
| EP3969590A4 (en) | 2024-05-15 |
| IL288040A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022714A2 (pt) | Moduladores e modulação do receptor para rna de produtos finais de glicação avançada | |
| DK3986866T3 (da) | Ioniserbare lipider til nukleinsyrelevering | |
| CO2020010783A2 (es) | Composiciones de virus adeno-asociadas para la transferencia de genes pah y métodos de uso de los mismos | |
| CY1124845T1 (el) | Μεθοδοι παροχης μονοκλωνου rna | |
| GB2579747A8 (en) | Methods and compositions for modulating splicing | |
| IL287100A (en) | Plasmid system | |
| MX2021000250A (es) | Secuencias 3 utr para estabilizacion de arn. | |
| MX2020011786A (es) | Oligomeros antisentido para tratamiento de afecciones y enfermedades. | |
| MX2020010687A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| CY1123853T1 (el) | Ρυθμιστες nrf2 | |
| CO2022015926A2 (es) | Compuestos y métodos para modular el empalme | |
| MX2018007237A (es) | Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus. | |
| MX2016016905A (es) | Ensamblaje de adn mediado por nucleasa. | |
| CO2022015925A2 (es) | Compuestos y métodos para modular el corte y empalme | |
| MX2018013157A (es) | Analogos de oligonucleotidos dirigidos a lmna humana. | |
| PT3558943T (pt) | Lípido catiónico ionizável para distribuição de arn | |
| CL2017002731A1 (es) | Adenovirus oncolítico que codifica una proteína b7 | |
| DOP2019000132A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO DE LAS MISMAS. | |
| EP3544435A4 (en) | RNA SPLICE MODULATION PROCESSES | |
| AR100238A1 (es) | Método para producir l-aminoácidos en corinebacterias mediante el uso de un sistema de escisión de glicina | |
| MY194170A (en) | Antisense nucleic acids | |
| EP3310169A4 (en) | Methods for modulating rna splicing | |
| MX2020004907A (es) | Modificacion genica del gen de proteina que contiene sh2 inducible por citoquina (cish). | |
| DK3722434T3 (da) | Plasmidsystem | |
| EP4285912A3 (en) | Compositions and methods for modulating ataxin 3 expression |